To receive daily emails from Breaking Christian News to your inbox CLICK HERE

"Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today." -Dr. Gerald Weissmann

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal (Federation of the American Societies for Experimental Biology) by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restored—without obvious toxic side effects.

"We hope that clinical trial studies in AD patients should yield an extended and a better quality of life as observed in mice upon TFP5 treatment," said Harish C. Pant, Ph.D., a senior researcher involved in the work from the Laboratory of Neurochemistry at the National Institute of Neurological Disorders at Stroke at the National Institutes of Health in Bethesda, MD. "Therefore, we suggest that TFP5 should be an effective therapeutic compound." (Photo by: Cécile Graat)

To make this discovery, Pant and colleagues used mice with a disease considered the equivalent of Alzheimer's. One set of these mice were injected with the small molecule TFP5, while the other was injected with saline as placebo. The mice, after a series of intraperitoneal injections of TFP5, displayed a substantial reduction in the various disease symptoms along with restoration of memory loss. In addition, the mice receiving TFP5 injections experienced no weight loss, neurological stress (anxiety) or signs of toxicity. The disease in the placebo mice, however, progressed normally as expected. TFP5 was derived from the regulator of a key brain enzyme, called Cdk5. The over activation of Cdk5 is implicated in the formation of plaques and tangles, the major hallmark of Alzheimer's disease.

"The next step is to find out if this molecule can have the same effects in people, and if not, to find out which molecule will," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Now that we know that we can target the basic molecular defects in Alzheimer's disease, we can hope for treatments far better—and more specific—than anything we have today."

To receive daily emails from Breaking Christian News to your inbox CLICK HERE

Dr. Alveda King: Happy New Year, Happy Birthday Uncle

Florida Joins Texas in Ending American Bar Association's 'Gatekeeper' Grip on Law Schools

Another Victory for Tom Fitton and Judicial Watch; Oregon Agrees to Clean 800,000 Names of Inactive Voters from Voter Rolls

Nick Shirley Drops Another Bombshell Video, Exposing Even More Fraud [Videos]

DHS: NY Times' 'Despicably Misleading Headline' Is Why Media Aren't Trusted

Hyde Amendment Absent from Trump Health Plan, but White House Promises 'Strongest Possible Pro-Life Protections'

Alaska Finally Complies With Federal Law Defunding Planned Parenthood from Medicaid

US Armada Nears Middle East amid Heartbreaking Stories from Iran: 'They're Shooting Their Children'

President Trump Receives an Historic Gift from Venezuela's Opposition Leader

Election Integrity Win: SCOTUS Greenlights Lawsuits against Late Mail-In Ballots; Opens Door to Nationwide Challenges

VP Vance's Tie-Breaking Vote Tanks Resolution Restricting Venezuela Military Actions

House Republicans Have Enough Votes to Hold Clintons in Contempt of Congress, Comer Reveals

Abortion 'Doctor' Won't Answer Congress on Whether Men Can Get Pregnant

Federal DHS Employee Doxxes Identities of Thousands of ICE and Border Patrol Agents and the Search Is ON

Father-in-Law of Renee Good Refuses to Blame ICE, Urges Americans to Turn to God

Prayer Alert: Rioters Smash into ICE Vehicles; Minneapolis Police Stand Down—Report

President Trump Threatens Invoking Insurrection Act as Minnesota Rioting Escalates, Endangering Federal Officers

Pentagon Moves Carrier Strike Group Toward Middle East as Iran Death Reports 'Incredibly Dire'

'Dilbert' Creator Scott Adams Dies at Age 68

Ambassador Huckabee Predicts a 'Complete Realignment of the Middle East' [VIDEO]

Steve Shultz, Managing Editor
Founder and Owner

Aimee Herd, Editor